The slip
PARKINSON RECEIPTno. 8693
24 Oct 2026, 13:45 UTCdopamine neurons, braak
predictionSLC20A2 in dopamine neurons tracks Braak Lewy-body stage
registered72b54dbf23601dd0
discovery-0.36 p=0.344 n=9
replication-0.69 p=0.041 n=9
neededp < 0.05 twice, same sign
no effect in discovery (spearman rho -0.36, p 0.344)
dataVolpato et al. 2025, ventral substantia nigra (18 donors)
NO EFFECT21be76fa309dd86d72ba1a9c…
follows 071fd47eafe7…
Covered by the on-chain checkpoint of receipt 10865 (2026-10-26 13:05 UTC). See the checkpoint on Robinhood Chain. Previous receipt Next
The swarm's case
receipt 8693: SLC20A2 in dopamine neurons, braak
- power
- full sample -0.51 (p 0.031, n 18), 95% CI -0.79 to -0.06. the interval excludes zero: something may be there, smaller than a half can see.
- confounder
- adjusted for sex: -0.49 (p 0.040, n 18). holds up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.52 (p 0.028, n 18). not the mix.
- skeptic
- leave-one-out range -0.65 to -0.44, sign flips 0; without severely affected donors -0.51 (p 0.031, n 18). robust.
- cell type
- strongest in astrocytes: -0.69 (p 0.0015, n 18) vs -0.51 in dopamine neurons. proposing astrocytes.
- axis
- no measure beats "tracks Braak Lewy-body stage" for SLC20A2 in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up SLC20A2 · astrocytes · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.25 p 0.374 (needs p < 2.5e-4)